Prevalence of neutralizing antibodies against poliovirus 1, 2, and 3 in healthcare professionals aged 20-50 years

Moraes, José Cassio de; Rujula, Maria Josefa Penon; Otsuka, Marcelo.
Rev. Paul. Pediatr. (Ed. Port., Online) ; 39: e2019354, 2021. tab, graf
Artículo en Inglés, Portugués | LILACS | ID: biblio-1155477

Documentos relacionados

  1. Polio eradication: Addressing the hurdles on the last mile.
  2. Immunogenicity of Oral Polio Vaccine and Salk Inactive Polio Vaccine Against Xinjiang Imported Type 1 Wild Poliovirus.
  3. Polio endgame finish is in sight.
  4. Regulations for the Manufacture and Control of Live Poliovirus Vaccine: International Experience and China's Path.
  5. Use of Inactivated Polio Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
  6. Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials.
  7. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
  8. Two-Year Duration of Immunity of Inactivated Poliovirus Vaccine: A Follow-up Study in Pakistan in 2020.
  9. Assessing the stability of polio eradication after the withdrawal of oral polio vaccine.
  10. Poliovirus outbreak in New York State, August 2022: qualitative assessment of immediate public health responses and priorities for improving vaccine coverage.